SCHEMBL316039

SCHEMBL316039

CC1CCC(C(=O)O)CC1.O=C1C=CC(=O)N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CCR6 P51684 1/20 0.41
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB1 P18505 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRB2 P47870 2/20 0.38
GABRA4 P48169 2/20 0.38
GABRE P78334 2/20 0.38
GABRA6 Q16445 2/20 0.38
GABRG1 Q8N1C3 2/20 0.38
GABRG3 Q99928 2/20 0.38
GABRQ Q9UN88 2/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29010933 0.82 GSK3A (0.61) GSK3AGSK3BCCR6
SCHEMBL20561062 0.81 GSK3A (0.44) GSK3AGSK3BCCR6GABRPGABRD
SCHEMBL4819951 0.81 PLG (0.43) GSK3AGSK3BCCR6GABRPGABRD
SCHEMBL8096130 0.80 ALDH1A1 (0.36) GSK3AGSK3BCCR6GABRPGABRD
SCHEMBL265529 0.79 LMNA (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL135662 0.79 LMNA (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL135660 0.79 LMNA (0.48) GABRPGABRDGABRA1GABRB1GABRG2
Bicarbonate SCHEMBL9841170 0.79 GSK3A (0.42) GSK3AGSK3BCCR6RAB9ALMNA
SCHEMBL6908741 0.77 LMNA (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL6914968 0.77 LMNA (0.46) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675480-B1 METHODS OF PREPARATION OF CONJUGATES IMMUNOGEN INC (US) 2018-12-26 EP claimed
US-9046528-B2 Cross-reactive determinants and methods for their identification NOVARTIS TIERGESUNDHEIT AG (CH) 2015-06-02 US claimed
EP-2227243-A2 A PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE Hanmi Pharmaceutical Co., Ltd. (KR) 2010-09-15 EP claimed
WO-2009069983-A2 A PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE HANMI PHARMACEUTICAL CO., LTD. (KR) 2009-06-04 WO claimed
EP-0787015-B1 SYNTHESIS OF TYPHOID FEVER VACCINE FROM A PLANT OR FRUIT POLYSACCHARIDE US GOV HEALTH & HUMAN SERV (US) 2002-02-27 EP claimed
WO-2024121380-A1 VACCINAL COMPOSITION AND ADJUVANT PIERRE FABRE MEDICAMENT (FR) 2024-06-13 WO disclosed
US-11998544-B2 Methods of using splicing modulators EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-06-04 US disclosed
CN-112367996-B Methods of using splice modulators 卫材R&D管理有限公司 2024-05-24 CN disclosed
US-11965005-B2 Multi-epitope vaccine for the treatment of Alzheimer's disease OTHAIR PROTHENA LIMITED (IE) 2024-04-23 US disclosed
US-11952406-B2 Multi-epitope vaccine for the treatment of Alzheimer's disease OTHAIR PROTHENA LIMITED (IE) 2024-04-09 US disclosed
US-11945807-B2 Splicing modulator antibody-drug conjugates and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-04-02 US disclosed
US-11945849-B2 Multi-epitope vaccine for the treatment of Alzheimer's disease OTHAIR PROTHENA LIMITED (IE) 2024-04-02 US disclosed
EP-0257754-A2 Synthetic peptides of human Papilloma virus THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1988-03-02 EP disclosed
EP-0251575-A1 Hepatitis delta diagnostics and vaccines, their preparation and use CHIRON CORPORATION (US) 1988-01-07 EP disclosed
EP-0208672-A1 Vaccines and diagnostics derived from bovine diarrhea virus REGION WALLONNE représentée par le Ministre des Technologies pour la Région wallonne dans ses attributions (BE) 1987-01-14 EP disclosed
US-4622223-A Broad spectrum vaccine against gonorrhea THE BOARD OF TRUSTEES FOR THE LELAND STANFORD UNIVERSITY (US) 1986-11-11 US disclosed
EP-0199480-A2 Hepatitis A virus vaccines CHIRON CORPORATION (US) 1986-10-29 EP disclosed
US-4584195-A POLYPEPTIDES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1986-04-22 US disclosed
EP-0170496-A2 Vaccine against urinary tract infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1986-02-05 EP disclosed
EP-0166548-A2 Broad spectrum vaccine against gonorrhea THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1986-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945807-B2 Splicing modulator antibody-drug conjugates and methods of use RBM17, RBM22, SF3B1 GSK3A 2321/4885GSK3B 2307/4885CCR6 3479/4885
US-11998544-B2 Methods of using splicing modulators SF3B1, RBM17, SF3B5 GSK3A 3496/4885GSK3B 3548/4885CCR6 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.